Opyl Limited

OPL

AU0000070856

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 02:11:03 2024-06-07 EDT			5-day change	1st Jan Change
0.026 ^AUD	+18.18%		+18.18%	-7.14%

06-06	Opyl Secures First TrialGen Contract with Brain Vector	MT
04-29	Opyl Expands TrialKey Coverage; Shares Up 38%	MT

ShareRoot Ltd Announces Cessation of Harvey Kaplan as Director

May 10, 2019 at 12:12 am

ShareRoot Ltd. announced the cessation of Harvey Kaplan as director effective 6 April 2019.

Latest news about Opyl Limited

Opyl Secures First TrialGen Contract with Brain Vector	06-05	MT
Opyl Expands TrialKey Coverage; Shares Up 38%	04-28	MT
Opyl to Divest Opin Business	04-22	MT
Opyl Receives Offer for Patient Recruitment Business	03-22	MT
Trial Screen Pty Ltd entered into a non-binding offer to acquire Opin business from Opyl Limited.	03-21	CI
Opyl Requests Trading Halt After Receiving Offer For Opin Business	03-20	MT
Opyl Chair Stepping Down in End-April	03-15	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Opyl Raises Nearly AU$900,000 from Rights Issue Shortfall Placement	02-09	MT
Opyl Grows Cash Receipts for Fiscal Q2	01-31	MT
Opyl Receives Commitments for Potential Shortfall	01-02	MT
Opyl Appoints Interim CEO	11-23	MT
Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer	11-23	CI
Opyl Secures R&D Tax Rebate for Fiscal Year 2023	23-09-22	MT
Opyl Limited Announces Appointment of Antanas Guoga as Director, Effective from September 4, 2023	23-09-05	CI
Opyl Limited Announces Board Update	23-09-03	CI
Opyl Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Opyl Limited Launches TrialKey MVP	23-08-23	CI
Opyl Limited Announces Senior Leadership Changes	23-07-05	CI
Opyl Limited Announces Resignation of Michelle Gallaher as CEO	23-07-05	CI
Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor	23-05-01	CI
Opyl Completes Issuance of Shortfall Shares	23-04-04	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Opyl Limited Provides Earnings Guidance for the Fiscal Second Half of 2023	23-02-26	CI
Opyl Limited Announces Resignation of Julian Chick as Non-Executive Director	23-02-13	CI

Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
OPYL LIMITED	-7.14%	2.92M
VEEVA SYSTEMS INC.	-3.28%	29.6B
PRO MEDICUS LIMITED	+31.35%	8.65B
SECTRA AB	+37.91%	4.42B
EVOLENT HEALTH, INC.	-28.14%	2.69B
VERADIGM INC.	-8.96%	1.6B
OMNICELL, INC.	-21.92%	1.36B
LUNIT INC.	-37.12%	1.1B
SIMULATIONS PLUS, INC.	+3.82%	924M
B-SOFT CO.,LTD.	-43.36%	791M